Avenacy announced it has launched Propofol Injectable Emulsion, USP in the United States as a therapeutic generic equivalent for Diprivan® as approved by the U.S. Food and Drug Administration. Propofol Injectable Emulsion, USP is an intravenous general anesthetic and sedation drug indicated for:
- Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age
- Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age
- Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients
- Sedation for Adult Patients in Combination with Regional Anesthesia
- Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients
Avenacy's Propofol Injectable Emulsion, USP is available in 200 mg/20 mL, 500 mg/50 mL, and 1,000 mg/100 mL single-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, Propofol Injectable Emulsion, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Propofol Injectable Emulsion, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.
Propofol Injectable Emulsion, USP had U.S. sales of approximately $315 million for the twelve months ending in December 2024.1
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!